- Alkermes plc is a global biopharmaceutical company focused on developing and commercializing products related to schizophrenia, bipolar disorder, multiple sclerosis, and recently oncology.
- Alkermes has three therapeutics on the market, 1 in Regulatory review (passed Phase 3) and a pipeline of 2 others alongside a swath of licensed products generating significant manufacturing/royalty revenues.
- Alkermes has three unique revenue catalysts for 2020-2021 which include, the VUMERITY product launch, +6% price increases for Aristada/Vivitrol, and a large volume resumption making up for Vivitrol COVID-19 losses.
- Alkermes is able to manage a developing industry due to a great biotechnological base, successful pharmaceutical partnerships with corporations like Biogen, and a focused field of specialization with defendable intellectual property.
- In summary, with stable marketed therapeutics, upside events such as the VUMERITY-resumption, and a pipeline that will innovate on top of a dominated market, Alkermes plc is a "buy" at a 3-month FYE price target of $17.46 (+5.5% upside).
For further details see:
Alkermes: Schizophrenia Drug Producer Taking Market Share, 5.5% 3-Month Upside